BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 11
- Registration Number
- NCT03978611
- Locations
- 🇺🇸
Local Institution - 0002, Los Angeles, California, United States
🇧🇪Local Institution - 0018, Bruxelles, Brussels, Belgium
🇧🇪Local Institution - 0016, Brussels, Belgium
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT03979248
- Locations
- 🇳🇱
PRA Health Sciences - Netherlands, Groningen, Netherlands
Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 135
- Registration Number
- NCT03956953
- Locations
- 🇨🇳
Local Institution, Beijing, Beijing, China
An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers
- Conditions
- Advanced Solid Cancers
- Interventions
- First Posted Date
- 2019-05-21
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 54
- Registration Number
- NCT03956680
- Locations
- 🇺🇸
Local Institution - 0003, Chicago, Illinois, United States
🇺🇸Local Institution - 0002, Nashville, Tennessee, United States
🇺🇸Local Institution - 0005, Saint Louis, Missouri, United States
A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 15
- Registration Number
- NCT03950960
- Locations
- 🇺🇸
PRA Health Sciences - Lenexa, Lenexa, Kansas, United States
An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT03943147
- Locations
- 🇺🇸
The Regents of The University of California, Los Angeles, California, United States
🇺🇸NewYork-Presbyterian Queens, Fresh Meadows, New York, United States
🇺🇸Northwell Health Physician Partners at Great Neck, Great Neck, New York, United States
Pharmacokinetic and Metabolism of [14^C] BMS-986177 in Healthy Male Participants
- First Posted Date
- 2019-05-07
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03939702
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of BMS-986205 in Healthy Participants
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2019-09-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT03936374
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 131
- Registration Number
- NCT03934216
- Locations
- 🇺🇸
Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
🇧🇪Local Institution - 0065, Brussels, Belgium
🇩🇪Charite Universitatsmedizin Berlin - Campus Virchow-Klinikum, Berlin, Germany
Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 16
- Registration Number
- NCT03930602
- Locations
- 🇺🇸
ICON Plc (PRA Health Sciences), Salt Lake City, Utah, United States